Company news
Revvity, Inc. (NYSE:RVTY) news
Revvity, Inc. news releases on 6ix. Latest, Oct 2, 2026: Revvity to Hold Earnings Call on November 3, 2026
Press releases & updates
Revvity to Hold Earnings Call on November 3, 2026
October 2, 2026
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
September 24, 2026
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
September 9, 2026
Revvity : Quarterly Report for Quarter Ending July 5, 2026 (Form 10-Q)
August 11, 2026
Revvity Announces Financial Results for the Second Quarter of 2026
August 4, 2026
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
July 20, 2026
Revvity to Hold Earnings Call on Tuesday, August 4, 2026
July 8, 2026
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
July 1, 2026
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
June 22, 2026
Revvity Announces Financial Results for the First Quarter of 2026
May 5, 2026
Revvity Showcases Integrated Cancer Research Solutions at AACR Annual Meeting 2026
April 16, 2026
Revvity to Hold Earnings Call on Tuesday, May 5, 2026
April 10, 2026
Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
April 9, 2026
Revvity : Annual Report for Fiscal Year Ending 12/28, 2025 (Form 10-K)
February 24, 2026
Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
February 5, 2026
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025
February 2, 2026
Revvity Board Declares Quarterly Dividend
January 26, 2026
Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance
January 12, 2026
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
January 9, 2026
Revvity to Present at J.P. Morgan Healthcare Conference
December 18, 2025
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery
December 16, 2025
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
December 4, 2025
Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy
November 10, 2025
Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities
November 10, 2025
Revvity to Present at Upcoming Investor Conferences
October 28, 2025
Revvity Announces Financial Results for the Third Quarter of 2025
October 27, 2025
Revvity Showcases Progress with Purpose in 2025 Impact Report
October 14, 2025
Revvity to Hold Earnings Call on Monday, October 27, 2025
October 6, 2025
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
October 2, 2025
Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis
September 29, 2025
Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems
September 22, 2025
Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina
September 2, 2025
Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics
August 6, 2025
Revvity Announces Financial Results for the Second Quarter of 2025
July 28, 2025
Revvity to Hold Earnings Call on Monday, July 28, 2025
July 7, 2025
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
June 2, 2025
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
May 19, 2025
Revvity Announces Financial Results for the First Quarter of 2025
April 28, 2025
Revvity to Hold Earnings Call on Monday, April 28, 2025
April 3, 2025
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
April 2, 2025
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
March 20, 2025
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
March 3, 2025
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
February 20, 2025